Actuate Therapeutics Inc(ACTU),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ACTU Actuate Therapeutics Inc

Closed 12-18 16:00:00 EST

7.02

+0.16

+2.33%

盘后7.02

+0.000.00%

16:10 EST

High7.11	Low6.66	Vol23.45K
Open6.86	D1 Closing6.86	Amplitude6.63%
Mkt Cap163.17M	Tradable Cap65.15M	Total Shares23.24M
T/O162.52K	T/O Rate0.25%	Tradable Shares9.28M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ACTU","market":"US","secType":"STK","nameCN":"Actuate Therapeutics Inc","latestPrice":7.02,"timestamp":1766091600000,"preClose":6.86,"halted":0,"volume":23449,"hourTrading":{"tag":"盘后","latestPrice":7.02,"preClose":7.02,"latestTime":"16:10 EST","volume":107,"amount":757.54,"timestamp":1766092204375},"delay":0,"floatShares":9280300,"shares":23243328,"eps":-1.204351,"marketStatus":"Closed","change":0.16,"latestTime":"12-18 16:00:00 EST","open":6.86,"high":7.1099,"low":6.655,"amount":162521.4294,"amplitude":0.066312,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.204351,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1766134800000},"marketStatusCode":5,"adr":0,"listingDate":1723521600000,"exchange":"NASDAQ","adjPreClose":6.86,"postHourTrading":{"tag":"盘后","latestPrice":7.02,"preClose":7.02,"latestTime":"16:10 EST","volume":107,"amount":757.54,"timestamp":1766092204375},"volumeRatio":0.281422},"requestUrl":"/m/hq/s/ACTU/tweets","defaultTab":"tweets","newsList":[{"id":"2592909049","title":"Actuate Therapeutics Announces Phase 2 Elraglusib Data for Metastatic Pancreatic Cancer Selected for ASCO GI 2026 Presentation","url":"https://stock-news.laohu8.com/highlight/detail?id=2592909049","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592909049?lang=en_us&edition=fundamental","pubTime":"2025-12-18 21:45","pubTimestamp":1766065527,"startTime":"0","endTime":"0","summary":"Actuate Therapeutics Announces Phase 2 Elraglusib Data for Metastatic Pancreatic Cancer Selected for ASCO GI 2026 Presentation. Actuate Therapeutics Inc. has announced that data from its Phase 2 clinical trial in metastatic pancreatic cancer will be featured in both an oral and poster presentation at the ASCO GI 2026 conference. The presentations are scheduled for January 9, 2026. The study evaluates the company’s lead investigational drug, elraglusib, a novel GSK-3β inhibitor targeting molecular pathways involved in tumor growth and resistance to conventional cancer therapies. The results are expected to be presented at the conference and have not yet been disclosed.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Actuate Therapeutics ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nNDL4SKPh1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","LU0314104364.USD","LU2095319765.USD","SG9999014013.SGD","BK4585","LU2210150020.SGD","BK4139","NDAQ","SG9999014039.USD","ACTU","SG9999014021.USD","SG9999014005.SGD","IE00BGHQF748.EUR","BK4112","LU2210149790.SGD","IE00BKPKM429.USD","IE00B3QW5Z07.USD","BK4588"],"gpt_icon":0},{"id":"2591417156","title":"Actuate Therapeutics Reports Positive Phase II Results for Elraglusib in Metastatic Salivary Gland Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2591417156","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591417156?lang=en_us&edition=fundamental","pubTime":"2025-12-15 21:45","pubTimestamp":1765806314,"startTime":"0","endTime":"0","summary":"Actuate Therapeutics Inc. has announced the publication of new Phase II clinical trial data evaluating elraglusib, a glycogen synthase kinase-3 beta  inhibitor, in combination with platinum chemotherapy , with or without sequential pembrolizumab immunotherapy, for patients with advanced, metastatic salivary gland cancers. The results, published in Clinical Cancer Research , show a median overall survival of 18.6 months, with 40% of patients alive at two years. The study enrolled 32 patients, including both adenoid cystic carcinoma (47%) and non-ACC (53%) subtypes, in partnership with the Dana-Farber Cancer Institute. Findings suggest that nuclear GSK-3β expression may help identify patients most likely to benefit from this treatment approach. The data have already been published and are available for review.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-gene","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nNDLtyvkh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU2210150020.SGD","LU2095319765.USD","BK4585","IE00BKPKM429.USD","SG9999014039.USD","SG9999014013.SGD","SG9999014021.USD","BK4112","IE00B64PRP62.GBP","IE00BGHQF748.EUR","LU0314104364.USD","BK4139","LU2210149790.SGD","IE00B3QW5Z07.USD","NDAQ","ACTU","SG9999014005.SGD"],"gpt_icon":0},{"id":"2587275846","title":"Actuate Therapeutics Signs $100M Sales Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2587275846","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2587275846?lang=en_us&edition=fundamental","pubTime":"2025-11-29 06:48","pubTimestamp":1764370127,"startTime":"0","endTime":"0","summary":"An update from Actuate Therapeutics, Inc. ( ($ACTU) ) is now available. On November 28, 2025, Actuate Therapeutics, Inc. entered into an At the Mar...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/actuate-therapeutics-signs-100m-sales-agreement?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/actuate-therapeutics-signs-100m-sales-agreement?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ACTU"],"gpt_icon":0},{"id":"2587301758","title":"BRIEF-Actuate Therapeutics Inc - Enters At The Market Issuance Sales Agreement With B. Riley And Craig-Hallum - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2587301758","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2587301758?lang=en_us&edition=fundamental","pubTime":"2025-11-29 06:28","pubTimestamp":1764368918,"startTime":"0","endTime":"0","summary":"BRIEF-Actuate Therapeutics Inc - Enters At The Market Issuance Sales Agreement With B. Riley And Craig-Hallum - SEC FilingNov 28  - Actuate Therapeutics Inc ACTU.O:ACTUATE THERAPEUTICS INC - MAY SELL COMMON STOCK UP TO $100 MILLION - SEC FILINGACTUATE THERAPEUTICS INC - ENTERS AT THE MARKET ISSUANCE SALES AGREEMENT WITH B. RILEY AND CRAIG-HALLUM - SEC FILINGFurther company coverage: ACTU.O ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251128:nFWN3X40LI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ACTU"],"gpt_icon":0},{"id":"2587875889","title":"Actuate Therapeutics Inc - Enters at the Market Issuance Sales Agreement With B. Riley and Craig-Hallum - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2587875889","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2587875889?lang=en_us&edition=fundamental","pubTime":"2025-11-29 06:23","pubTimestamp":1764368587,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251128:nFWN3X40LI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ACTU"],"gpt_icon":0},{"id":"2587758893","title":"Actuate Therapeutics Inc - May Sell Common Stock up to $100 Mln - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2587758893","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2587758893?lang=en_us&edition=fundamental","pubTime":"2025-11-29 06:23","pubTimestamp":1764368587,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251128:nFWN3X40LI:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ACTU"],"gpt_icon":0},{"id":"2584943964","title":"Actuate Therapeutics Price Target Maintained With a $20.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2584943964","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584943964?lang=en_us&edition=fundamental","pubTime":"2025-11-19 19:42","pubTimestamp":1763552520,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ACTU/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 19, 2025 06:42 ET (11:42 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACTU"],"gpt_icon":0},{"id":"2583507537","title":"Craig-Hallum Reaffirms Their Buy Rating on Actuate Therapeutics, Inc. (ACTU)","url":"https://stock-news.laohu8.com/highlight/detail?id=2583507537","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583507537?lang=en_us&edition=fundamental","pubTime":"2025-11-14 22:45","pubTimestamp":1763131515,"startTime":"0","endTime":"0","summary":"Craig-Hallum analyst Albert Lowe maintained a Buy rating on Actuate Therapeutics, Inc. today and set a price target of $25.00. Lowe covers the Heal...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/craig-hallum-reaffirms-their-buy-rating-on-actuate-therapeutics-inc-actu-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/craig-hallum-reaffirms-their-buy-rating-on-actuate-therapeutics-inc-actu-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ACTU"],"gpt_icon":0},{"id":"2583548422","title":"Actuate Therapeutics Q3 EPS $(0.25) Beats $(0.28) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2583548422","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583548422?lang=en_us&edition=fundamental","pubTime":"2025-11-14 06:44","pubTimestamp":1763073896,"startTime":"0","endTime":"0","summary":"Actuate Therapeutics (NASDAQ:ACTU) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.28) by 10.07 percent. This is a 54.55 percent increase over losses of $(0.55) per share","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48853453/actuate-therapeutics-q3-eps-0-25-beats-0-28-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Actuate Therapeutics Q3 EPS $(0.25) Beats $(0.28) Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACTU"],"gpt_icon":0},{"id":"2569879172","title":"Actuate Therapeutics Price Target Maintained With a $20.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2569879172","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569879172?lang=en_us&edition=fundamental","pubTime":"2025-09-23 18:50","pubTimestamp":1758624600,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ACTU/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  September 23, 2025 06:50 ET (10:50 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACTU"],"gpt_icon":0},{"id":"2569822827","title":"Actuate Therapeutics - Data to Support FDA and Ema Submissions Beginning Later This Year, Continuing Into Early 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2569822827","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569822827?lang=en_us&edition=fundamental","pubTime":"2025-09-22 20:45","pubTimestamp":1758545100,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250922:nTUA95ZVFJ:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ACTU"],"gpt_icon":0},{"id":"2569822387","title":"Actuate Therapeutics Inc - Recent Financing Extends Runway Through Key Regulatory Points","url":"https://stock-news.laohu8.com/highlight/detail?id=2569822387","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569822387?lang=en_us&edition=fundamental","pubTime":"2025-09-22 20:45","pubTimestamp":1758545100,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250922:nTUA95ZVFJ:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ACTU"],"gpt_icon":0},{"id":"2569782284","title":"Actuate Therapeutics Inc: Amended Elraglusib Ind Application With Updated Clinical Data From Phase 2 Trial for Metastatic Pancreatic Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2569782284","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569782284?lang=en_us&edition=fundamental","pubTime":"2025-09-22 20:45","pubTimestamp":1758545100,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250922:nTUA95ZVFJ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ACTU","BK4139"],"gpt_icon":0},{"id":"2569780991","title":"Actuate Therapeutics Provides FDA with Updated Clinical Data Package to Support Planned Regulatory Interactions with FDA and EMA Over the Coming Months","url":"https://stock-news.laohu8.com/highlight/detail?id=2569780991","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569780991?lang=en_us&edition=fundamental","pubTime":"2025-09-22 20:45","pubTimestamp":1758545100,"startTime":"0","endTime":"0","summary":"Elraglusib represents a potential back bone therapy in pancreatic cancer with three ongoing trials in combination with current standards of care and novel immunotherapiesRecent financing provides exte","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/09/22/3153932/0/en/Actuate-Therapeutics-Provides-FDA-with-Updated-Clinical-Data-Package-to-Support-Planned-Regulatory-Interactions-with-FDA-and-EMA-Over-the-Coming-Months.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EMA","BK4081","BK4139","ACTU"],"gpt_icon":0},{"id":"2566119399","title":"Actuate Therapeutics Announces Closing of $17.25 Million Public Offering of Common Stock, Including Full Exercise of Over-Allotment Option","url":"https://stock-news.laohu8.com/highlight/detail?id=2566119399","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566119399?lang=en_us&edition=fundamental","pubTime":"2025-09-12 04:01","pubTimestamp":1757620860,"startTime":"0","endTime":"0","summary":"CHICAGO and FORT WORTH, Texas, Sept.  11, 2025  (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on develo","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/09/11/3148863/0/en/Actuate-Therapeutics-Announces-Closing-of-17-25-Million-Public-Offering-of-Common-Stock-Including-Full-Exercise-of-Over-Allotment-Option.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","BK4139","BK4539","ACTU","BK4007"],"gpt_icon":0},{"id":"2566602548","title":"Actuate Therapeutics Shares Drop After Public Offering Prices","url":"https://stock-news.laohu8.com/highlight/detail?id=2566602548","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566602548?lang=en_us&edition=fundamental","pubTime":"2025-09-10 21:50","pubTimestamp":1757512200,"startTime":"0","endTime":"0","summary":"Actuate Therapeutics shares were 23% lower, at $6.56, after the company said it has priced an underwritten public offering of 2.1 million shares at $7 a share.The biopharmaceutical company said it has granted the underwriters a 30-day option to buy up to 321,000 additional shares at the public offering price per share, less underwriting discounts and commissions.The company intends to use the proceeds from the proposed offering for working capital and general corporate purposes.The offering is expected to close Thursday, subject to the satisfaction of customary closing conditions.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4007","LENZ","BK4539","ACTU"],"gpt_icon":0},{"id":"2566609990","title":"BRIEF-Actuate Therapeutics Announces Pricing of $15.0 Million Public Offering of Common Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2566609990","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566609990?lang=en_us&edition=fundamental","pubTime":"2025-09-10 20:43","pubTimestamp":1757508221,"startTime":"0","endTime":"0","summary":"BRIEF-Actuate Therapeutics Announces Pricing of $15.0 Million Public Offering of Common StockSept 10 (Reuters) - Actuate Therapeutics Inc ACTU.O:ACTUATE THERAPEUTICS ANNOUNCES PRICING OF $15.0 MILLION","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250910:nTUA8BBDFX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACTU","BK4139"],"gpt_icon":0},{"id":"2566465086","title":"Actuate Therapeutics Plans Public Offering of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2566465086","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566465086?lang=en_us&edition=fundamental","pubTime":"2025-09-10 05:39","pubTimestamp":1757453959,"startTime":"0","endTime":"0","summary":"Actuate Therapeutics  said late Tuesday it plans a public offering of common shares.The company intends to grant underwriters a 30-day overallotment option to buy up to an additional 15% of the shares.The company said it plans to use net proceeds for general corporate purposes.Shares of Actuate Therapeutics were down more than 16% in after-hours trading.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4539","BK4139","LENZ","ACTU","BK4007"],"gpt_icon":0},{"id":"2566051648","title":"Actuate Therapeutics Announces Proposed Public Offering of Common Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2566051648","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566051648?lang=en_us&edition=fundamental","pubTime":"2025-09-10 04:07","pubTimestamp":1757448420,"startTime":"0","endTime":"0","summary":"CHICAGO and FORT WORTH, Texas, Sept.  09, 2025  (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on develo","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/09/09/3147344/0/en/Actuate-Therapeutics-Announces-Proposed-Public-Offering-of-Common-Stock.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4139","BK4539","LENZ","ACTU"],"gpt_icon":0},{"id":"2564335752","title":"BRIEF-Actuate Therapeutics Inc Files For Mixed Shelf Offering Of Up To $250 Million- SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2564335752","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564335752?lang=en_us&edition=fundamental","pubTime":"2025-09-03 05:47","pubTimestamp":1756849674,"startTime":"0","endTime":"0","summary":"BRIEF-Actuate Therapeutics Inc Files For Mixed Shelf Offering Of Up To $250 Million- SEC FilingActuate Therapeutics Inc ACTU.O:ACTUATE THERAPEUTICS INC FILES FOR MIXED SHELF OFFERING OF UP TO $250 MILLION- SEC FILINGSource text: [ID:n0001683168-25-006622]Further company coverage: ACTU.O","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250902:nFWN3UP0G7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACTU","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.actuatetherapeutics.com","stockEarnings":[{"period":"1week","weight":-0.0974},{"period":"1month","weight":0.1588},{"period":"3month","weight":-0.0007},{"period":"6month","weight":-0.0817},{"period":"1year","weight":-0.1044},{"period":"ytd","weight":-0.1382}],"compareEarnings":[{"period":"1week","weight":-0.0235},{"period":"1month","weight":0.0086},{"period":"3month","weight":0.0138},{"period":"6month","weight":0.1298},{"period":"1year","weight":0.1111},{"period":"ytd","weight":0.1456}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"exchange":"NASDAQ","name":"Actuate Therapeutics Inc","nameEN":"Actuate Therapeutics Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Actuate Therapeutics Inc(ACTU),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Actuate Therapeutics Inc(ACTU) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Actuate Therapeutics Inc,ACTU,Actuate Therapeutics Inc股票,Actuate Therapeutics Inc股票老虎,Actuate Therapeutics Inc股票老虎国际,Actuate Therapeutics Inc行情,Actuate Therapeutics Inc股票行情,Actuate Therapeutics Inc股价,Actuate Therapeutics Inc股市,Actuate Therapeutics Inc股票价格,Actuate Therapeutics Inc股票交易,Actuate Therapeutics Inc股票购买,Actuate Therapeutics Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Actuate Therapeutics Inc(ACTU),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Actuate Therapeutics Inc(ACTU) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction